ArticleCureus2026
Generalized Morphea Successfully Treated With Tripterygium Glycosides and Hydroxychloroquine: A Case Report and a Systematic Review.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Generalized morphea, a rare and severe variant of localized scleroderma, is marked by extensive skin involvement with multiple hardened plaques and hyperpigmentation. The pathogenesis of generalized morphea is still unclear, and there is no established therapy. The aim of this article is to present a novel treatment approach for generalized morphea while also conducting a systematic review of previously published cases to summarize and analyze the clinical features and current effective treatment strategies for this condition. We herein describe the case of a 61-year-old male patient with generalized morphea successfully treated with tripterygium glycosides (TG) and hydroxychloroquine (HCQ). The systematic review analyzed a total of 77 patients with generalized morphea, comprising 76 previously reported cases (57 adults and 19 children) and one adult patient from our article. Compared with the adult group, the pediatric group demonstrated significantly higher rates of abnormal antinuclear antibodies (78.9%, p=0.002) and a greater proportion of severe cases (89.5%, p=0.001). Furthermore, systemic glucocorticoid is currently the most frequently used and effective treatment (p=0.016). In the treatment of generalized morphea, the combination of HCQ and TG may represent a potentially useful therapeutic option worthy of further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.